Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lithocholic acid is a **secondary bile acid** formed by bacterial action in the colon, specifically through reduction of the hydroxyl group at the 7-position of chenodeoxycholic acid. It acts primarily as a **detergent to solubilize fats for absorption** in the intestine[1][2][3]. While lithocholic acid is considered **toxic to hepatocytes at high concentrations** and has been implicated as a **carcinogen** (due to its ability to induce oxidative stress, DNA damage, and promote tumorigenesis), recent studies also suggest potential beneficial effects. These include **anti-inflammatory actions** in the colon, **activation of the TGR5 receptor**, and selective cytotoxicity against various malignancies[1][2][3][4]. LCA is also an **agonist of the vitamin D receptor**, binds NAPE-PLD to influence lipid signaling, and has shown **anti-aging effects in preclinical models**[1]. It is not currently an approved pharmaceutical but is the focus of ongoing preclinical and mechanistic research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lithocholic acid.